TEL AVIV, Israel, Feb. 28, 2024 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to lead compound, LUT014, a novel topically applied B-Raf inhibitor, for the treatment of EGFR (Epidermal Growth Factor Receptor) inhibitor induced acneiform rash. Currently, no drug or treatment is approved by the FDA for the prevention or treatment of EGFR inhibitor induced acneiform lesions.
TEL AVIV, Israel, March 17, 2023 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced the presentation of data from a real-world analysis of skin toxicity from EGFR inhibitors and the associated unmet challenge, in an e-poster at the 2023 American Academy of Dermatology (AAD) Annual Meeting being held March 17-21, in New Orleans, LA. The analysis was supported, in part, by Lutris Pharma and the intramural research program of the National Institutes of Health (NIH).
TEL AVIV, Israel, Feb. 16, 2023 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that Antoni Ribas, M.D., Ph.D., Chairman and Founder of Lutris Pharma, will present a company overview, virtually, at the 16th Annual European Life Sciences CEO Forum on March 8, 2023.
TEL AVIV, Israel, Oct. 24, 2022 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that the California Institute of Regenerative Medicine (CIRM) has awarded company Founder and Chairman of the Board, Antoni Ribas, M.D., Ph.D., Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), a $5.0 million grant to be used for the further development of Lutris Pharma's LUT017 gel, a novel, small molecule inhibitor of BRAF, for skin regeneration and wound healing.
Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today...
TEL AVIV, Israel, May 10, 2022 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that Antoni Ribas, M.D., Ph.D., has been appointed as Chairman of the Board of Directors. Dr. Ribas, Founder of Lutris Pharma, has been a director of the company since its inception.
TEL AVIV, Israel, Oct. 5, 2021 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that, based on the compelling results observed in part one, it has initiated part two of its phase 1/2 trial of lead compound, LUT014, a topically applied, novel B-Raf inhibitor, for the treatment of radiation-induced dermatitis (RD) in breast cancer patients.
 Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that the first U.S. patients have been dosed as part of the Company's phase 2 trial of lead compound, LUT014, a topically applied, novel B-Raf inhibitor, for metastatic colorectal cancer patients (mCRC) being treated with epidermal growth factor receptor (EGFR) inhibitor therapy who have developed dose-limiting acneiform lesions.